Australia markets closed

AIM ImmunoTech Inc. (AIM)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
1.41000.0000 (0.00%)
At close: 04:00PM EST
1.4400 +0.03 (+2.13%)
Pre-market: 08:58AM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.4100
Bid1.3500 x 800
Ask1.5400 x 1100
Day's range1.3510 - 1.4400
52-week range1.1100 - 3.0600
Avg. volume345,722
Market cap67.467M
Beta (5Y monthly)-0.91
PE ratio (TTM)N/A
EPS (TTM)-0.3780
Earnings date16 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.88
  • GlobeNewswire

    AIM ImmunoTech Provides Third Quarter 2021 Business Update

    OCALA, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the third quarter ended September 30, 2021 and provides a business update. Third Quarter 2021 Financial Highlights: As of September 30, 2021, AIM had cash, cash equivalents and marketable securities of $53.7 million, compared to $54.4 million as of December 31, 2020. Research and development expenses for the three months ended September 30, 2021 were $2.0 million, compared to $

  • GlobeNewswire

    AIM ImmunoTech Submits IND and Accompanying Fast Track Application for Phase 2 Trial of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer

    OCALA, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the U.S. Food and Drug Administration (FDA) for a planned Phase 2 study of the company’s drug Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. The planned AMP-270 clinical trial of approximately 250 subjects will be a Phase 2, rand

  • GlobeNewswire

    AIM ImmunoTech Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intranasal Therapy

    CHDR Table 1 CHDR Table 1 CHDR Table 2 CHDR Table 2 OCALA, Fla., Oct. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today released detailed safety data from a Phase 1 clinical study which supports the company’s belief that its drug Ampligen has significant potential as an intranasal therapeutic for COVID-19. AIM previously announced that the study to assess the safety, tolerability and biological activity of Ampligen as a potential intranasal therapy was completed, and th